Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Dong Li, Jianqing Xu, Zhuozhi Wang, Zhen Gong, Jieying Liu, Yong Zheng, Jian Li & Jing Li. (2017) Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1. mAbs 9:4, pages 628-637.
Read now
Read now
Articles from other publishers (18)
David Hodson, Hitesh Mistry, Sofia Guzzetti, Michael Davies, Anna Staniszewska, Paul Farrington, Elaine Cadogan, James Yates, Leon Aarons & Kayode Ogungbenro. (2023)
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the
DNA
damage response pathway
. CPT: Pharmacometrics & Systems Pharmacology 12:11, pages 1640-1652.
Crossref
Crossref
Carmen Criscitiello, Elena Guerini-Rocco, Giulia Viale, Caterina Fumagalli, Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Marco Invernizzi, Umberto Malapelle & Nicola Fusco. (2022) Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently
Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry 22:4, pages 787-800.
Crossref
Crossref
Julianne D. Twomey & Baolin Zhang. (2021) Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. The AAPS Journal 23:2.
Crossref
Crossref
Lingyu Tian, Jiaqiang Ma, Lijie Ma, Bohao Zheng, Longzi Liu, Danjun Song, Yining Wang, Zhao Zhang, Qiang Gao, Kang Song & Xiaoying Wang. (2020) PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World Journal of Surgical Oncology 18:1.
Crossref
Crossref
Raffaella Mormile. (2019) EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?. Pathology & Oncology Research 25:4, pages 1665-1666.
Crossref
Crossref
Tzu Rong Peng & Ta Wei Wu. (2019) Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer. American Journal of Therapeutics 26:4, pages e537-e538.
Crossref
Crossref
Fabrice Barlesi, Edward B. Garon, Dong-Wan Kim, Enriqueta Felip, Ji-Youn Han, Joo-Hang Kim, Myung-Ju Ahn, Mary Jo Fidler, Matthew A. Gubens, Gilberto de CastroJr.Jr., Veerle Surmont, Qiao Li, Anne C. Deitz, Gregory M. Lubiniecki & Roy S. Herbst. (2019) Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC. Journal of Thoracic Oncology 14:5, pages 793-801.
Crossref
Crossref
Stefano Gay, Giovanni Rossi, Giuliana Corica, Giulia Graziani, Carlo Genova, Erika Rijavec, Marco Tagliamento, Francesco Grossi & Massimo Giusti. (2019) Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study. Endocrine.
Crossref
Crossref
Fang Liu, Beno�t Sansas, Xavier Pr�ville, Romain Gineste, Jialei Wang, Hui Yu, Xia Meng, Romain Micol & Luc Barraud. (2018) Elevated IL‑6/IL‑1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort. Molecular and Clinical Oncology.
Crossref
Crossref
Zehuan Li, Yiran Qiu, Weiqi Lu, Ying Jiang & Jin Wang. (2018) Immunotherapeutic interventions of Triple Negative Breast Cancer. Journal of Translational Medicine 16:1.
Crossref
Crossref
Jingsi Dong, Bingjie Li, Qinghua Zhou & Depei Huang. (2018) Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. Journal of Evidence-Based Medicine 11:4, pages 278-287.
Crossref
Crossref
Sujit Nair & Adrián LLerena. (2018) New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics. Drug Metabolism and Personalized Therapy 33:2, pages 61-64.
Crossref
Crossref
Jun Li, Hui-Chen Hsu, John D. Mountz & John G. Allen. (2018) Unmasking Fucosylation: from Cell Adhesion to Immune System Regulation and Diseases. Cell Chemical Biology 25:5, pages 499-512.
Crossref
Crossref
Pınar Ö. Eser & Pasi A. Jänne. (2018) TGFβ pathway inhibition in the treatment of non-small cell lung cancer. Pharmacology & Therapeutics 184, pages 112-130.
Crossref
Crossref
Arik Dahan, Milica Markovic, Svetlana Epstein, Noa Cohen, Ellen M. Zimmermann, Aaron Aponick & Shimon Ben-Shabat. (2017) Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease. European Journal of Pharmaceutical Sciences 108, pages 78-85.
Crossref
Crossref
Lijun Dong, Dan Lei & Haijun Zhang. (2017) Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. Oncotarget 8:38, pages 64600-64606.
Crossref
Crossref
Rance C. Siniard & Shuko Harada. (2017) Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Archiv 471:2, pages 209-219.
Crossref
Crossref
Lawrence M Agius. (2017) Dimensions of Niche-Induced Anti-Apoptosis of Therapeutically Resistant Neoplasms in Radio-Chemo-Therapy. International Journal of Radiology & Radiation Therapy 2:3.
Crossref
Crossref